1. Scrip
  2. >>R&D
  3. >>Clinical Trials

AstraZeneca's Pipeline Reaps Rewards Of Return To Science

 
• By Alexandra Shimmings

AstraZeneca rounded off a busy 2017 full of R&D highs, but some huge lows, with a full Phase III pipeline that it says shows how far the company has come since Pascal Soriot took the reins in 2012 and spearheaded a renewed focus on science. But will the company become a victim of its own success?

female scientist working with microscope
• Source: Shutterstock

A year of "unprecedented" activity and a Phase III pipeline brimming over with products allowed AstraZeneca PLC to claim at an R&D day on Dec. 14 that its focus on science in the five years since CEO Pascal Soriot arrived has changed the culture of its business.

Sean Bohen, chief medical officer and EVP of global medicines development told analysts that the sheer number of positive results...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Pipeline Watch: Eight Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

The Rise of China Biopharma – Five Themes In 2025

 
• By Andrew McConaghie

The growth of China’s biopharma sector has been perhaps the most significant sector trend this year – Scrip outlines five themes that have emerged during 2025 and in discussions at the recent Jefferies conference in London.

Amycretin Heads For Phase III In Type 2 Diabetes

 
• By Joseph Haas

New Phase II data in type 2 diabetes for Novo Nordisk’s GLP-1/amylin agonist amycretin shows significant weight loss and HbA1c-lowering potential. A Phase III trial is planned.

Kelonia Draws Attention With In Vivo CAR-T Myeloma Data

 
• By Alaric DeArment

The biotech will present data at the upcoming ASH meeting on three patients who achieved PRs or VGPRs with minimal residual disease negativity and no cases of neurotoxicity.

More from R&D

Amycretin Heads For Phase III In Type 2 Diabetes

 
• By Joseph Haas

New Phase II data in type 2 diabetes for Novo Nordisk’s GLP-1/amylin agonist amycretin shows significant weight loss and HbA1c-lowering potential. A Phase III trial is planned.

Kelonia Draws Attention With In Vivo CAR-T Myeloma Data

 
• By Alaric DeArment

The biotech will present data at the upcoming ASH meeting on three patients who achieved PRs or VGPRs with minimal residual disease negativity and no cases of neurotoxicity.

Zai Lab Takes Lead In DLL3 Lung Cancer ADC Race

 
• By Andrew McConaghie

Having built its reputation as the ‘Gateway to China’ for global firms, Zai is going global itself, moving its potential first-in-class ADC into Phase III development.